Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1/2 reversion mutations in a pan-cancer cohort.

Cancer science - 1 Feb 2024

Nakamura Kohei, Hayashi Hideyuki, Kawano Ryutaro, Ishikawa Marin, Aimono Eriko, Mizuno Takaaki, Kuroda Hajime, Kojima Yasuyuki, Niikura Naoki, Kawanishi Aya, Takeshita Kei, Suzuki Shinsuke, Ueno Shinichi, Okuwaki Kosuke, Sasaki Jiichiro, Yamaguchi Masatoshi, Masuda Kenta, Chiyoda Tatsuyuki, Yamagami Wataru, Okada Chihiro, Nohara Sachio, Tanishima Shigeki, Nishihara Hiroshi

Abstract excerpt

Tumor sensitivity to platinum (Pt)-based chemotherapy and poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors is increased by homologous recombination deficiency-causing mutations; in particular, reversion mutations cause drug resistance by restoring protein function. Treatment response is predicted by breast cancer susceptibility gene 1/2 (BRCA1/2) mutations; however, BRCA1/2 reversion mutations have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA2 Protein
Share to Germ-Line Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ovarian Neoplasms

Share to BRCA1 Protein

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Poly(ADP-ribose) Polymerases

Source

Open in PubMed Open full text

Identifiers

PMID: 38041241
DOI: 10.1111/cas.16033
PMCID: PMC10859608

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2 reversion mutations in a pan-cancer cohort.PMID 38041241Read ↗

Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer PatientsSemantic proximity Read ↗

Reversion mutations in germline BRCA1/2-mutant tumors reveal a BRCA-mediated phenotype in non-canonical histologies.Semantic proximity Read ↗

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.Semantic proximity Read ↗

A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.Semantic proximity Read ↗

Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance.Semantic proximity Read ↗

Reversion mutations define minimal <i>BRCA1/2</i> requirements for therapy resistanceSemantic proximity Read ↗

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.Semantic proximity Read ↗

A meta-analysis of clinical cases of reversion mutations in <i>BRCA</i> genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistanceSemantic proximity Read ↗

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors.Semantic proximity Read ↗

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in <i>BRCA1/2</i> -mutant metastatic breast cancerSemantic proximity Read ↗

Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.Semantic proximity Read ↗

Decoding the <i>BRCA2</i> reversion principles underlying PARP inhibitor resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.